Mona Khanya, Ntlantsana Vuyokazi, Tomita Andrew M, Paruk Saeeda
Discipline of Psychiatry, School of Clinical Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Department of Psychiatry, KwaZulu Natal Research Innovation and Sequencing Platform (KRISP), College of Health Sciences, University of KwaZulu- Natal, Durban, South Africa.
S Afr J Psychiatr. 2022 Oct 21;28:1927. doi: 10.4102/sajpsychiatry.v28i0.1927. eCollection 2022.
There is a high prevalence of cannabis use in patients with schizophrenia spectrum and other psychotic disorders, with comorbid cannabis use in this population being associated with poorer long-term outcomes.
To determine the prevalence of cannabis use in patients with a schizophrenia spectrum and other psychotic disorders.
The study was conducted at a psychiatric hospital in Durban, KwaZulu-Natal Province, South Africa.
A review of clinical records of patients admitted to the hospital for the period, June 2018 to June 2020, was conducted.
A total of 370 clinical records were reviewed, of which 48.9% reported current and 51.1% lifetime cannabis use. Being male was significantly associated with current and lifetime cannabis use (OR = 4.90, 95% CI 2.49-9.62 and OR = 6.27, 95% CI 3.28-11.95, respectively). Current alcohol use was also associated with current cannabis use (CCU) (OR = 3.06, 95% CI 1.78-5.28), and age 45 years and older was associated with a lower odds of cannabis use (OR = 0.30, 95% CI 0.09-0.96). Forty-eight per cent of participants were admitted three or more times, and readmission was associated with cannabis use ( = 0.01). There was a lack of association between cannabis use, readmission and human immunodeficiency virus (HIV) status, after controlling for variables such as alcohol use and gender.
Almost 50% of people admitted with schizophrenia spectrum and other psychotic disorders have comorbid current and lifetime cannabis use. There is a need for dual diagnosis units to address comorbid substance use in people with psychotic disorders, as it leads to poorer outcomes.
The study found that there is a high prevalence of cannabis use in people with psychosis. Therefore, it is imperative that we revise treatment programs in our psychiatric units and there is an urgent need for dual diagnosis programs that address substance use in this group of patients.
精神分裂症谱系及其他精神障碍患者中大麻使用的患病率很高,该人群中合并大麻使用与较差的长期预后相关。
确定精神分裂症谱系及其他精神障碍患者中大麻使用的患病率。
该研究在南非夸祖鲁 - 纳塔尔省德班的一家精神病医院进行。
对2018年6月至2020年6月期间入院患者的临床记录进行回顾。
共审查了370份临床记录,其中48.9%报告当前使用大麻,51.1%报告终生使用大麻。男性与当前及终生大麻使用显著相关(OR = 4.90,95%CI 2.49 - 9.62;OR = 6.27,95%CI 3.28 - 11.95)。当前饮酒也与当前大麻使用相关(OR = 3.06,95%CI 1.78 - 5.28),45岁及以上年龄与大麻使用几率较低相关(OR = 0.30,95%CI 0.09 - 0.96)。48%的参与者入院三次或更多次,再入院与大麻使用相关(P = 0.01)。在控制饮酒和性别等变量后,大麻使用、再入院与人类免疫缺陷病毒(HIV)状态之间缺乏关联。
近50%患有精神分裂症谱系及其他精神障碍的入院患者合并有当前及终生大麻使用。需要设立双重诊断科室来处理精神障碍患者的合并物质使用问题,因为这会导致更差的预后。
该研究发现精神病患者中大麻使用的患病率很高。因此,我们必须修订精神科的治疗方案,并且迫切需要针对该组患者物质使用问题的双重诊断项目。